Belviq (Obesity) - Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 03/24/2014 -- Reportstack, provider of premium market research reports announces the addition of Belviq (Obesity) - Forecast and Market Analysis to 2022 market report to its offering
Belviq (Obesity) - Forecast and Market Analysis to 2022


After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Belviq (lorcaserin), a product of Arena Pharmaceuticals, was the second anti-obesity drug to arrive in the market after a long pharmacotherapy hiatus, coming nine months after the launch of Vivus Qsymia as one of the main competitors. It is not yet approved in any of the European markets, Canada, Brazil, or Japan. The publisher forecasts that Belviq will not reach the European market until 2018, the Canadian market until 2017, and the Brazilian market until 2016. Arena and its marketing partner, Eisai, have given no indication of any plans to launch Belviq in Japan.


- Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Belviq including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Belviq for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Belviq performance
- Obtain sales forecast for Belviq from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604